6 results about "Insulin activity" patented technology

The invention discloses a dynamic blood glucose monitoring and intelligent pump speed adjusting system and method, and relates to the technical field of biomedical engineering.The dynamic blood glucose monitoring and intelligent pump speed adjusting method comprises the steps that precise monitoring is conducted through a multi-mode sensing module, an enzyme electrode sensor adopts an anti-interference coating, a Raman spectrum dynamic correction algorithm is combined, and motion artifacts and temperature drift are restrained; the metabolic feature fusion calibration module is integrated with a time convolution network, time sequence modeling is carried out on diet, exercise and historical blood glucose data, an individualized metabolic parameter database is constructed, and self-adaptive signal drift compensation is achieved; the self-adaptive pump control module innovatively designs a double-layer fuzzy PID controller, a base layer generates an infusion rate according to a real-time blood glucose state and insulin activity, an optimization layer introduces an LSTM metabolism prediction model, and the slope of an infusion curve is dynamically adjusted in combination with future behavior pre-judgment; in the edge-cloud collaborative architecture, a lightweight TCN model is locally deployed to guarantee real-time control, and a cloud end optimizes a global digital twinborn model through federal learning and generates a multi-dimensional metabolic risk early warning report.

The present application relates to a kind of polyoxovanadomolybdate nanoclusters and its preparation method and application.The chemical general formula of the polyoxovanadomolybdate nanocluster is Na6[V 10‑x Mo x O 28 ]·nH2O, wherein 1≤x≤4, n is the number of crystallization water, the value range is 8~12.The polyoxovanadomolybdate nanocluster provided by the present application is by Mo substitution part V atom in dodecanovanadate lattice, into lattice in substitutional doping form, on the basis of retaining parent body POV insulin-like activity, give treatment agent excellent antioxidant function, and through the combined action of antioxidant and insulin-like activity, realize the multiple regulation of diabetic wound microenvironment, promote wound healing.

Provided is a fusion protein formed from an insulin analogue and a single-domain antibody specifically binding to human serum albumin (HSA). By binding to HAS, the half-life of insulin is prolonged by means of an FcRn-mediated recycling effect. Moreover, the single-domain antibody has a shielding effect on the fusion-expressed insulin analogue, whereby the insulin activity can be regulated to achieve a sustained-release effect. Further provided are a single-domain antibody specifically binding to human serum albumin (HSA), or an antigen-binding fragment thereof, and a derivative containing the single-domain antibody or the antigen-binding fragment thereof.

A pharmaceutical formulation presented, comprising an insulin or an insulin analog, and at least one protective excipient, in high concentration, selected from: a protective osmolyte, a surfactant, and a phenolic preservative. In embodiments, the insulin or insulin analog is one or more of: regular human insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin detemir, or insulin degludec. In some embodiments, at least one of: the concentration of the protective osmolyte confers an osmolarity greater than 250 mOsm / L, the concentration of the surfactant is greater than 0.1% w / v, or the concentration of the phenolic preservative is greater than 0.4% w / v. In some embodiments, insulin API is dissolved and incubated for 20 to 40 minutes at high pH before the protective excipients are added.

The invention discloses an insulin pump control method and system based on blood glucose data, and relates to the technical field of insulin infusion control, and the method comprises the steps: obtaining real-time blood glucose sequence data and historical infusion record data, and carrying out the preprocessing; constructing an insulin pharmacokinetic attenuation model to calculate an in-transit insulin residual activity value; inputting the standardized blood glucose time series data into a Bayesian neural network prediction model to generate prediction uncertainty distribution parameters; calculating a prediction confidence index according to the prediction variance and comparing the prediction confidence index with a threshold value to obtain a confidence judgment result; selecting a dose optimization strategy or a conservative control strategy according to a confidence coefficient judgment result to calculate an insulin infusion dose; infusion is executed, and historical records are updated; the prediction uncertainty is quantified through the Bayesian neural network, the in-transit insulin activity is accurately modeled in combination with the pharmacokinetic model, and the control strategy is dynamically switched according to the confidence, so that the control error amplification caused by prediction misjudgment is effectively avoided, and the delayed hypoglycemia caused by the insulin superposition effect is prevented.

An insulin monitoring system includes one or more processors, one or more computer-readable storage devices, and program instructions stored on at least one of the one or more storage devices for execution by at least one of the one or more processors. The program instructions include: first program instructions to track, in real time, the amount of insulin active in a patient; second program instructions to calculate the amount of insulin need of the patient by tracking the patient's metabolic states; third program instructions to compare the insulin active in the patient with the insulin need of the patient; and fourth program instructions to determine an insulin fault level based on the comparison.